Follow
Ahmet Zehir
Ahmet Zehir
VP, Bioinformatics
Verified email at natera.com - Homepage
Title
Cited by
Cited by
Year
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
30342019
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
28922017
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
18982017
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for …
DT Cheng, TN Mitchell, A Zehir, RH Shah, R Benayed, A Syed, ...
The Journal of molecular diagnostics 17 (3), 251-264, 2015
17112015
Inherited DNA-repair gene mutations in men with metastatic prostate cancer
CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ...
New England Journal of Medicine 375 (5), 443-453, 2016
15442016
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled …
H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ...
Journal of clinical oncology 36 (7), 633, 2018
12152018
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium, AACR Project GENIE Consortium, ...
Cancer discovery 7 (8), 818-831, 2017
12132017
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ...
Science 359 (6375), 582-587, 2018
9842018
Variant review with the integrative genomics viewer
JT Robinson, H Thorvaldsdóttir, AM Wenger, A Zehir, JP Mesirov
Cancer research 77 (21), e31-e34, 2017
8762017
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
7822018
Clinical sequencing defines the genomic landscape of metastatic colorectal cancer
R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ...
Cancer cell 33 (1), 125-136. e3, 2018
6712018
Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes
CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ...
Cell stem cell 21 (3), 374-382. e4, 2017
6552017
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
5632017
Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade
W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ...
JAMA oncology 5 (4), 471-478, 2019
5272019
Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
W Abida, J Armenia, A Gopalan, R Brennan, M Walsh, D Barron, D Danila, ...
JCO precision oncology 1, 1-16, 2017
4892017
Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer
A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ...
Journal of clinical oncology 37 (4), 286, 2019
4852019
Genome doubling shapes the evolution and prognosis of advanced cancers
CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ...
Nature genetics 50 (8), 1189-1195, 2018
4672018
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
JP Solomon, I Linkov, A Rosado, K Mullaney, EY Rosen, D Frosina, ...
Modern Pathology 33 (1), 38-46, 2020
4492020
Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing
D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, ...
Jama 318 (9), 825-835, 2017
4442017
Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ...
Science 364 (6439), 485-491, 2019
4342019
The system can't perform the operation now. Try again later.
Articles 1–20